Entinostat as Immunotherapy
ENCORE 601 / KEYNOTE 142NCT02437136
Collaboration with Merck
A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination With Pembrolizumab in Patients With Non-small Cell Lung Cancer, With Expansion Cohorts in Patients With Non-small Cell Lung Cancer and Melanoma.
Collaboration with Genentech
A Randomized, Placebo-controlled, Double-blind Phase 2 Study of Atezolizumab With or Without Entinostat in Patients with Metastatic Triple Negative Breast Cancer, with a Phase 1b Lead in Phase.
Collaboration with Merck KGaA and Pfizer
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment With a Safety Lead-in
Entinostat in HR+ Breast Cancer
Sponsored by NCI/ECOG-ACRIN Cancer Research Group
A Randomized Phase 3 Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor Positive Advanced Breast Cancer.